Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the n-terminus via oxime formation with 18F-4-fluorobenzaldehyde

Bioconjugate Chemistry

Volumn 25, Issue 1, 2014, Pages 82-92

  Rosik, Daniel ^a   Thibblin, Alf ^b   Antoni, Gunnar ^b,c   Honarvar, Hadis ^d   Strand, Joanna ^d   Selvaraju, Ram Kumar ^c   Altai, Mohamed ^d   Orlova, Anna ^c   Eriksson Karlström, Amelie ^a   Tolmachev, Vladimir ^d  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; MAMMALS; MOLECULAR IMAGING; MOLECULES; PEPTIDES; RADIOACTIVITY; SCAFFOLDS; SCAFFOLDS (BIOLOGY); SYNTHESIS (CHEMICAL);

AFFIBODY MOLECULES; BIODISTRIBUTIONS; FUNCTIONALIZED; HIGH CONTRAST; IMAGING MODALITY; IN-VIVO IMAGING; LABELINGS; N TERMINUS; OXIME FORMATION; PROTEIN SCAFFOLDS;

TUMORS;

4 FLUOROBENZALDEHYDE F 18; AMINOOXYACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; OXIME; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SPACER DNA; TRACER; TRIGLUTAMYL SPACER; UNCLASSIFIED DRUG; 4-FLUOROBENZALDEHYDE; AFFIBODY (ZHER2-342)2; BENZALDEHYDE DERIVATIVE; FLUORINE; HYBRID PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FLUORINATION; IMAGING SYSTEM; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MOLECULAR IMAGING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; RADIOACTIVITY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; DIAGNOSTIC USE; HUMAN; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BENZALDEHYDES; CELL LINE, TUMOR; FLUORINE RADIOISOTOPES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; OXIMES; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892751639     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400343r     Document Type: Article

References (48)

1. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation Cell. 144, 646-674
2. van Dongen, G. A., Poot, A. J., and Vugts, D. J. (2012) PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET Tumour Biol. 33, 607-615
3. Tolmachev, V., Stone-Elander, S., and Orlova, A. (2010) Current approaches to the use of radiolabeled tyrosine kinase-targeting drugs for patient stratification and treatment response monitoring: prospects and pitfalls Lancet Oncol. 11, 992-1000
4. van Dongen, G. A., Visser, G. W., Lub-de Hooge, M. N., de Vries, E. G., and Perk, L. R. (2007) Immuno-PET: a navigator in monoclonal antibody development and applications Oncologist 12, 1379-1389
5. McCabe, K. E. and Wu, A. M. (2010) Positive progress in immunoPET - not just a coincidence Cancer Biother. Radiopharm. 25, 253-261
6. Schmidt, M. M. and Wittrup, K. D. (2009) A modeling analysis of the effects of molecular sizeand binding affinity on tumor targeting Mol. Cancer Ther. 8, 2861-2871
7. Nygren, P. A. (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold FEBS J. 275, 2668-2676
8. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., StaÌŠhl, S., and Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 66, 4339-4348
9. Tolmachev, V., Rosik, D., Wallberg, H., Sjoberg, A., Sandstrom, M., Hansson, M., Wennborg, A., and Orlova, A. (2010) Imaging of EGFR expression in murine xenografts using site-specifically labeled anti-EGFR 111In-DOTA-ZEGFR: 2377 Affibody molecule: aspect of the injected tracer amount Eur. J. Nucl. Med. Mol. Imaging 37, 613-622
10. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T., Frejd, F. Y., Höidén-Guthenberg, I., Varasteh, Z., Orlova, A., Tolmachev, V., StaÌŠhl, S., and Löfblom, J. (2013) Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification PLoS One 8, e62791
11. Lindborg, M., Cortez, E., Hoiden-Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F., Morrison, M., Abrahmsen, L., Herne, N., Pietras, K., and Frejd, F. Y. (2011) Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo J. Mol. Biol. 407, 298-315
12. Tolmachev, V., Malmberg, J., Hofstrom, C., Abrahmsen, L., Bergman, T., Sjoberg, A., Sandstrom, M., Graslund, T., and Orlova, A. (2012) Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551 J. Nucl. Med. 53, 90-97
13. Tolmachev, V. (2008) Imaging of HER-2 overexpression in tumors for guiding therapy Curr. Pharm. Des. 14, 2999-3011
14. Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., and Feldwisch, J. (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules J. Nucl. Med. 51, 892-897
15. Sandberg, D., Wennborg, A., Feldwisch, F., Tolmachev, V., Carlsson, J., Garske, U., Sörensen, J., and Lindman, H. (2012) First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer J. Nucl. Med. 53 (Supplement 1) 220
16. Tolmachev, V. and Orlova, A. (2010) Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets Curr. Med. Chem. 17, 2636-5265
17. WaÌŠllberg, H., Grafström, J., Cheng, Q., Lu, L., Martinsson Ahlzén, H. S., Samén, E., Thorell, J. O., Johansson, K., DunaÌŠs, F., Olofsson, M. H., Stone-Elander, S., Arnér, E. S., and StaÌŠhl, S. (2012) HER2-positive tumors imaged within 1 h using a site-specifically 11C-labeled Sel-tagged affibody molecule J. Nucl. Med. 53, 1446-5143
18. Kramer-Marek, G., Kiesewetter, D. O., Martiniova, L., Jagoda, E., Lee, S. B., and Capala, J. (2008)) [(18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography Eur. J. Nucl. Med. Mol. Imaging. 35, 1008-1018
19. Namavari, M., Padilla De Jesus, O., Cheng, Z., De, A., Kovacs, E., Levi, J., Zhang, R., Hoerner, J. K., Grade, H., Syud, F. A., and Gambhir, S. S. (2008) Direct site-specific radiolabeling of an affibody protein with 4-[(18)F]fluorobenzaldehyde via oxime chemistry Mol. Imaging Biol. 10, 177-181
20. Heskamp, S., Laverman, P., Rosik, D., Boschetti, F., van der Graaf, W. T., Oyen, W. J., van Laarhoven, H. W., Tolmachev, V., and Boerman, O. C. (2012) Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer J. Nucl. Med. 53, 146-153
21. Miao, Z., Ren, G., Liu, H., Jiang, L., and Cheng, Z. (2010) Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein Bioconjugate Chem. 21, 947-954
22. Tolmachev, V., Velikyan, V., Sandström, M., and Orlova, A. (2010) A HER2-binding Affibody molecule labeled with 68Ga for PET imaging. Direct in vivo comparison with 111In-labelled analogue Eur. J. Nucl. Med. Mol. Imaging 37, 1356-1367
23. Kramer-Marek, G., Shenoy, N., Seidel, J., Griffiths, G. L., Choyke, P., and Capala, J. (2011) 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET Eur. J. Nucl. Med. Mol. Imaging. 38, 1967-1976
24. Mume, E., Orlova, A., Larsson, B., Nilsson, A. S., Nilsson, F. Y., Sjöberg, S., and Tolmachev, V. (2005) Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody Bioconjugate Chem. 16, 1547-1655
25. Orlova, A., WaÌŠllberg, H., Stone-Elander, S., and Tolmachev, V. (2009) On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J. Nucl. Med. 50, 417-425
26. Tolmachev, V. and Stone Elander, S. (2010) Radiolabelled proteins for Positron Emission Tomography: pros and cons of labeling methods Biochim. Biophys. Acta 1800, 487-510
27. McBride, W. J., Sharkey, R. M., Karacay, H., D'Souza, C. A., Rossi, E. A., Laverman, P., Chang, C. H., Boerman, O.C., and Goldenberg, D. M. (2009) A novel method of 18F radiolabeling for PET J. Nucl. Med. 50, 991-998
28. Glaser, M. and Arstad, E. (2007) ″Click labeling″ with 2-[18f]fluoroethylazide for positron emission tomography Bioconjugate Chem. 18, 989-993
29. Campbell-Verduyn, L. S., Mirfeizi, L., Schoonen, A. K., Dierckx, R. A., Elsinga, P. H., and Feringa, B. L. (2011) Strain-promoted copper-free ″click″ chemistry for 18F radiolabeling of bombesin Angew. Chem., Int. Ed. 50, 11117-11120
30. Li, Z., Cai, H., Hassink, M., Blackman, M. L., Brown, R. C., Conti, P. S., and Fox, J. M.. (2010) Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes Chem. Commun. 46, 8043-8045
31. Poethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs J. Nucl. Med. 45, 892-902
32. Cheng, Z., De Jesus, O. P., Namavari, M., De, A., Levi, J., Webster, J. M., Zhang, R., Lee, B., Syud, F. A., and Gambhir, S. S. (2008) Small-animal PET imaging of Human Epidermal Growth Factor Receptor Type 2 expression with site-specific 18F-labeled protein scaffold molecules J. Nucl. Med. 49, 804-813
33. Miao, Z., Ren, G., Jiang, L., Liu, H., Webster, J. M., Zhang, R., Namavari, M., Gambhir, S.S., Syud, F., and Cheng, Z. (2011) A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor Eur. J. Nucl. Med. Mol. Imaging 38, 1977-1984
34. Disibio, G. and French, S. W. (2008) Metastatic patterns of cancers: results from a large autopsy study Arch. Pathol. Lab. Med. 132, 931-939
35. Rosik, D., Orlova, A., Malmberg, J., Altai, M., Varasteh, Z., Sandström, M., Eriksson Karlström, A., and Tolmachev, V. (2012) Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging Eur. J. Nucl. Med. Mol. Imaging 39, 693-702
36. Hosseinimehr, S. J., Tolmachev, V., and Orlova, A. (2012) Factors influencing liver uptake of radiolabelled targeting protein and peptides: consideration for design of targeting conjugate peptide Drug Discovery Today 17, 1224-1232
37. Tran, T., Engfeldt, T., Orlova, A., Sandström, M., Feldwisch, J., Abrahmsen, L., Wennborg, A., Tolmachev, V., and Eriksson Karlström, A. (2007) 99mTc-maEEE-ZHER2:342, an Affibody molecule-based tracer for detection of HER2-expression in malignant tumors Bioconjugate Chem. 18, 1956-1964
38. Tolmachev, V., Hofström, C., Malmberg, J., Ahlgren, S., Hosseinimehr, S. J., Sandström, M., Abrahmsén, L., Orlova, A., and Gräslund, T. (2010) HEHEHE-Tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99mTc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation Bioconjugate Chem. 21, 2013-2022
39. Tran, T. A., Rosik, D., Abrahmsén, L., Sandström, M., Sjöberg, A., WaÌŠllberg, H., Ahlgren, S., Orlova, A., and Tolmachev, V. (2009) Design, synthesis and biological evaluation of a HER2-specific affibody molecule for molecular imaging Eur. J. Nucl. Med. Mol. Imaging 36, 1864-73
40. Engfeldt, T., Orlova, A., Tran, T., Bruskin, A., Widström, C., Eriksson Karlström, A., and Tolmachev, V. (2007) Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence Eur. J. Nucl. Med. Mol. Imaging 34, 722-33
41. Tolmachev, V., Tran, T. A., Rosik, D., Abrahmsén, L., Sjöberg, A., and Orlova, A. (2012) Tumor targeting using Affibody molecules: interplay of affinity, target expression level and binding site composition J. Nucl. Med. 53, 953-960
42. WaÌŠllberg, H. and Orlova, A. (2008) Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers Cancer Biother. Radiopharm. 23, 435-442
43. Strand, J., Honarvar, H., Perols, A., Orlova, A., Selvaraju, R. K., Karlström, A. E., and Tolmachev, V. (2013) Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts PLoS One 8, e70028
44. Behr, T. M., Goldenberg, D. M., and Becker, W. (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations Eur. J. Nucl. Med. 25, 201-212
45. Pantelouris, E. M. and Lintern-Moore, S. (1978) Physiological Studies on the Nude Mouse. The Nude Mouse in Experimental and Clinical Research (Fogh, J., Ed.) pp 29-31, Chapter 3, Academic Press, New York.
46. Engfeldt, T., Tran, T., Orlova, A., Widström, C., Feldwisch, J., Abrahmsen, L., Wennborg, A., Karlström, A. E., and Tolmachev, V. (2007) 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule Eur. J. Nucl. Med. Mol. Imaging 34, 1843-1453
47. Tran, T., Engfeldt, T., Orlova, A., Widström, C., Bruskin, A., Tolmachev, V., and Karlström, A. E. (2007) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules Bioconjugate Chem. 18, 549-658
48. Tran, T. A, Ekblad, T., Orlova, A., Sandström, M., Feldwisch, J., Wennborg, A., Abrahmsén, L., Tolmachev, V., and Eriksson Karlström, A. (2008) Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules Bioconjugate Chem. 19, 2568-2576